Overview

Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions

Status:
Terminated
Trial end date:
2007-10-22
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, multicenter phase III trial to assess the efficacy of early administration of zoledronate versus observation in delaying bone-related symptoms in metastatic breast cancer patients.
Phase:
Phase 3
Details
Lead Sponsor:
Spanish Breast Cancer Research Group
Collaborator:
Novartis
Treatments:
Diphosphonates
Zoledronic Acid